Depression.
When the antidepressants and the therapy have not been enough, advanced treatment may be the bridge that finally moves things.
What we mean by depression.
Depression that does not respond fully to first- and second-line treatments is often called treatment-resistant depression. It is more common than most people realize, and it is the single most frequent reason patients arrive at Renue.
Conventional antidepressants work for many people, but not for everyone, and not always quickly. For the patients they do not fully reach, advanced options like Spravato® and IV Ketamine can deliver meaningful, often rapid, improvement, frequently within the first few sessions.
Our job is to evaluate honestly whether one of these pathways is a reasonable next step for you, and to deliver it inside a setting that respects both the seriousness of the condition and the dignity of the person living with it.
3 possible pathways, matched to you.
Final recommendations are made after a complete clinical evaluation. We will explain why we are suggesting a particular pathway, in writing, before anything begins.
- Pathway 0101
Spravato®
FDA-approved specifically for treatment-resistant depression.
Spravato® (esketamine) is the only FDA-approved nasal spray indicated for adults whose depression has not responded adequately to other antidepressants. Used together with an oral antidepressant and delivered under REMS-certified supervision, many patients describe meaningful changes within the first one to four weeks.
Learn more about Spravato® - Pathway 0202
IV Ketamine
Rapid, controlled relief via IV infusion.
IV Ketamine delivers a precisely dosed sub-anesthetic infusion in a private suite. Because bioavailability is essentially complete, the therapeutic response is often the fastest and most consistent of the three pathways, with many patients reporting shifts within the first few sessions.
Learn more about IV Ketamine - Pathway 0303
KAP
Pair pharmacology with focused psychological work.
For depression that is tangled with grief, trauma, or longstanding patterns, Ketamine-Assisted Psychotherapy can help translate the openness of a ketamine session into durable change through structured preparation and integration.
Learn more about KAP
~30%
of patients with major depression are considered treatment-resistant
2019
FDA approval year for Spravato® in treatment-resistant depression
Days
Many patients describe initial shifts within the first sessions, not months
You do not have to know what pathway is right. That is our job.
A consultation is a conversation, not a commitment. We will tell you honestly whether advanced treatment is appropriate for your situation, and if it is not, we will help you think about what is.
Every treatment is delivered under medical supervision.
Medical disclaimer. Treatment decisions are made only after a clinical consultation. Outcomes may vary. Information presented here is educational and not a substitute for medical advice. If you are in crisis, call or text 988. For emergencies, call 911.
Ready to begin?
Request a free consultation and our clinical team will help you understand your options.